Tag: cx 2024
Questions linger: BASIL-3 does not find for drug-eluting technologies for CLTI
In the UK National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA)-funded BASIL-3 randomised controlled trial (RCT), neither drug-coated balloon (DCB)...
“We know which DCB to use”—but many other questions remain in...
A first-time presentation of five-year data from the IN.PACT AV Access study evaluating the IN.PACT AV (Medtronic) drug-coated balloon (DCB) today led principal investigator...
Paclitaxel controversy: Yes, device restrictions did cause harm
“Unfortunately, we are doing worse for our patients today,” were the sobering thoughts of Eric Secemsky (Beth Israel Deaconess Medical Center, Boston, USA) during...
Debates to unpick controversies in aortic repair at CX 2024
Debates will shed new light on controversies in the treatment of aortic disease at the 2024 Charing Cross (CX) Symposium, alongside practical sessions with...
Why treat DVT interventionally with a “wall-to-wall” mechanical thrombectomy approach?
In a recent interview, Marie Josee van Rijn from Rotterdam, the Netherlands and Emma Wilton from Oxford, UK, provided insight into the transformative power...
Endovascular showdown: CX 2024 sets the stage for BASIL-3 first-time data...
At the Charing Cross (CX) Symposium 2024 (23–25 April, London, UK), Andrew Bradbury (University of Birmingham, Birmingham, UK) and the BASIL-3 team of triallists...
